The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents

Jeffrey R. Curtis, Fenglong Xie, Lang Chen, John W. Baddley, Timothy Beukelman, Kenneth G. Saag, Claire Spettell, Raechele M. McMahan, Joaquim Fernandes, Kevin Winthrop, Elizabeth Delzell

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Background: It is unclear whether anti-tumour necrosis factor alpha and biological agents with different mechanisms of action have similar safety. This study evaluated the incidence of hospitalised infections among rheumatoid arthritis (RA) patients starting or switching various biological agents. Methods: Using a database from a large US healthcare organisation from January 2005 to August 2009, the authors identified enrollees with RA and their treatment episodes entailing the new use of a biological agent, stratified by no biological use in the previous year ('biological-free') or switching from a different biological agent ('switchers'). Outcomes were hospitalised infections identified using previously validated algorithms. Proportional hazards models estimated the hazard ratio of hospitalised infections, comparing each biological agent with infliximab. Results: Among 7847 biological treatment episodes, 63% were for biological-free patients and 37% for switchers. There were 364 hospitalised infections. Rates of hospitalised infection among biologicalfree patients and switchers were 4.6 and 7.0 per 100 person-years, respectively (p

Original languageEnglish (US)
Pages (from-to)1401-1406
Number of pages6
JournalAnnals of the Rheumatic Diseases
Volume70
Issue number8
DOIs
StatePublished - Aug 2011

Fingerprint

Biological Factors
Rheumatoid Arthritis
Infection
Hazards
Proportional Hazards Models
Cohort Studies
Tumor Necrosis Factor-alpha
Databases
Delivery of Health Care
Safety
Therapeutics

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Allergy

Cite this

The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. / Curtis, Jeffrey R.; Xie, Fenglong; Chen, Lang; Baddley, John W.; Beukelman, Timothy; Saag, Kenneth G.; Spettell, Claire; McMahan, Raechele M.; Fernandes, Joaquim; Winthrop, Kevin; Delzell, Elizabeth.

In: Annals of the Rheumatic Diseases, Vol. 70, No. 8, 08.2011, p. 1401-1406.

Research output: Contribution to journalArticle

Curtis, JR, Xie, F, Chen, L, Baddley, JW, Beukelman, T, Saag, KG, Spettell, C, McMahan, RM, Fernandes, J, Winthrop, K & Delzell, E 2011, 'The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents', Annals of the Rheumatic Diseases, vol. 70, no. 8, pp. 1401-1406. https://doi.org/10.1136/ard.2010.146365
Curtis, Jeffrey R. ; Xie, Fenglong ; Chen, Lang ; Baddley, John W. ; Beukelman, Timothy ; Saag, Kenneth G. ; Spettell, Claire ; McMahan, Raechele M. ; Fernandes, Joaquim ; Winthrop, Kevin ; Delzell, Elizabeth. / The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. In: Annals of the Rheumatic Diseases. 2011 ; Vol. 70, No. 8. pp. 1401-1406.
@article{ecbc78d9c1e14b48b0e47b61d2600b86,
title = "The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents",
abstract = "Background: It is unclear whether anti-tumour necrosis factor alpha and biological agents with different mechanisms of action have similar safety. This study evaluated the incidence of hospitalised infections among rheumatoid arthritis (RA) patients starting or switching various biological agents. Methods: Using a database from a large US healthcare organisation from January 2005 to August 2009, the authors identified enrollees with RA and their treatment episodes entailing the new use of a biological agent, stratified by no biological use in the previous year ('biological-free') or switching from a different biological agent ('switchers'). Outcomes were hospitalised infections identified using previously validated algorithms. Proportional hazards models estimated the hazard ratio of hospitalised infections, comparing each biological agent with infliximab. Results: Among 7847 biological treatment episodes, 63{\%} were for biological-free patients and 37{\%} for switchers. There were 364 hospitalised infections. Rates of hospitalised infection among biologicalfree patients and switchers were 4.6 and 7.0 per 100 person-years, respectively (p",
author = "Curtis, {Jeffrey R.} and Fenglong Xie and Lang Chen and Baddley, {John W.} and Timothy Beukelman and Saag, {Kenneth G.} and Claire Spettell and McMahan, {Raechele M.} and Joaquim Fernandes and Kevin Winthrop and Elizabeth Delzell",
year = "2011",
month = "8",
doi = "10.1136/ard.2010.146365",
language = "English (US)",
volume = "70",
pages = "1401--1406",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "8",

}

TY - JOUR

T1 - The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents

AU - Curtis, Jeffrey R.

AU - Xie, Fenglong

AU - Chen, Lang

AU - Baddley, John W.

AU - Beukelman, Timothy

AU - Saag, Kenneth G.

AU - Spettell, Claire

AU - McMahan, Raechele M.

AU - Fernandes, Joaquim

AU - Winthrop, Kevin

AU - Delzell, Elizabeth

PY - 2011/8

Y1 - 2011/8

N2 - Background: It is unclear whether anti-tumour necrosis factor alpha and biological agents with different mechanisms of action have similar safety. This study evaluated the incidence of hospitalised infections among rheumatoid arthritis (RA) patients starting or switching various biological agents. Methods: Using a database from a large US healthcare organisation from January 2005 to August 2009, the authors identified enrollees with RA and their treatment episodes entailing the new use of a biological agent, stratified by no biological use in the previous year ('biological-free') or switching from a different biological agent ('switchers'). Outcomes were hospitalised infections identified using previously validated algorithms. Proportional hazards models estimated the hazard ratio of hospitalised infections, comparing each biological agent with infliximab. Results: Among 7847 biological treatment episodes, 63% were for biological-free patients and 37% for switchers. There were 364 hospitalised infections. Rates of hospitalised infection among biologicalfree patients and switchers were 4.6 and 7.0 per 100 person-years, respectively (p

AB - Background: It is unclear whether anti-tumour necrosis factor alpha and biological agents with different mechanisms of action have similar safety. This study evaluated the incidence of hospitalised infections among rheumatoid arthritis (RA) patients starting or switching various biological agents. Methods: Using a database from a large US healthcare organisation from January 2005 to August 2009, the authors identified enrollees with RA and their treatment episodes entailing the new use of a biological agent, stratified by no biological use in the previous year ('biological-free') or switching from a different biological agent ('switchers'). Outcomes were hospitalised infections identified using previously validated algorithms. Proportional hazards models estimated the hazard ratio of hospitalised infections, comparing each biological agent with infliximab. Results: Among 7847 biological treatment episodes, 63% were for biological-free patients and 37% for switchers. There were 364 hospitalised infections. Rates of hospitalised infection among biologicalfree patients and switchers were 4.6 and 7.0 per 100 person-years, respectively (p

UR - http://www.scopus.com/inward/record.url?scp=79959790816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959790816&partnerID=8YFLogxK

U2 - 10.1136/ard.2010.146365

DO - 10.1136/ard.2010.146365

M3 - Article

C2 - 21586439

AN - SCOPUS:79959790816

VL - 70

SP - 1401

EP - 1406

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 8

ER -